Wells Fargo & Company Galectin Therapeutics Inc Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Wells Fargo & Company holds 7,254 shares of GALT stock, worth $17,554. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,254
Previous 7,582
4.33%
Holding current value
$17,554
Previous $12,000
41.67%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding GALT
# of Institutions
65Shares Held
7.63MCall Options Held
61.2KPut Options Held
0-
Vanguard Group Inc Valley Forge, PA1.98MShares$4.79 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.26MShares$3.06 Million0.01% of portfolio
-
Black Rock Inc. New York, NY713KShares$1.72 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA567KShares$1.37 Million0.0% of portfolio
-
Geneos Wealth Management Inc.409KShares$989,4170.05% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $144M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...